S-P "blocked Subutex generic" in France

17 December 2007

The expiry of the patent on Schering-Plough's psychotropic drug Subutex (buprenorphine) has generated a commercial battle in the French market as the country's Council for Competition (CC) says that the US drug major used "all the means possible" to prevent a competing generic version from being launched. The CC has ruled in favor of the Australian company Arrow Generics, which had made a formal complaint to the authority.

Subutex was S-P's best selling drug in France, with sales of 85.0 million euros ($145.8 million) annually. Ahead of the patent expiry in March 2006, the company reportedly tried to head off competing generics by offering pharmacies special deals including delays on payment and discounts. The Council said pharmacy stocking capacity was saturated with Subutex in the two months preceding the launch of the Arrow generic, dissuading pharmacies from buying in supplies of the latter drug.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight